In this on-demand webinar, Head of Immunology, Noel Smith, PhD, explores how our integrated toolbox — combining in silico screening, the GS® expression system, and human immune cell assays — supports early identification of developability and immunogenicity risks, helping you prioritize the right candidates faster and avoid costly setbacks later in development.
Watch on demand to learn how this proactive approach can strengthen candidate selection while reducing risk and accelerating your clinical development path.
Key learning points
- Spot risks early: Identify developability and immunogenicity risks at the earliest stages, before they impact timelines, cost, or success of your program.
- Screen smarter: Learn how combining in silico and in vitro approaches enables faster, more informed lead candidate selection and optimization without sacrificing the depth of your early data package.
- Decide with confidence: Explore how a toolbox approach enables making confident, data-driven decisions to prioritize the right candidates and avoid costly setbacks, setting your molecule up for a smoother path to the clinic.
